The V-val subtype Epstein-Barr virus nuclear antigen 1 promotes cell survival after serum withdrawal

Chao,Mei; Wang,Hsiao-Ning; Lu,Yi Jin; Chang,Yu-Sun; Yu,Jau-Song

doi:10.3892/or.2014.3625

The V-val subtype Epstein-Barr virus nuclear antigen 1 promotes cell survival after serum withdrawal

Authors:
- Mei Chao
- Hsiao-Ning Wang
- Yi Jin Lu
- Yu-Sun Chang
- Jau-Song Yu
View Affiliations

Affiliations: Division of Microbiology, Graduate Institute of Biomedical Sciences, Chang Gung University, Kwei-Shan, Tao-Yang 333, Taiwan R.O.C., Molecular Medicine Research Center, College of Medicine, Chang Gung University, Kwei-Shan, Tao-Yang 333, Taiwan R.O.C.
Published online on: November 25, 2014 https://doi.org/10.3892/or.2014.3625
Pages: 958-966

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Epstein-Barr virus (EBV) can establish latent infection and has been associated with various human cancers. Epstein-Barr nuclear antigen 1 (EBNA1) is the only viral protein that is expressed in all EBV-associated malignant tissues. The N- and C-terminal domains of EBNA1, which are connected by internal glycine/alanine-rich short repeat sequences of various sizes, show sequence divergence across EBV strains isolated from around the world. At least five subtypes have been described, according to the amino acid at residue 487: P-ala, P-thr, V-val, V-pro, and V-leu. Whether the variations of EBNA-1 contribute to the pathogenesis of EBV or simply reflect the geographical distribution of EBV remain to be investigated. Furthermore, the cell effects conferred by EBNA1 subtypes that differ from that of the B95.8 prototype, which belongs to the P-ala subtype, remain to be elucidated. In this study, PCR was amplified with the full-length V-val EBNA1 gene from the CG3 cell line, an EBV-carrying lymphoblastoid cell line derived from a Taiwanese chronic myeloid leukemia patient. Plasmids expressing His-tagged EBNA1 fusion proteins in E. coli were constructed and used to raise antibodies in rabbit. The V-val EBNA1 gene was then cloned into a eukaryotic expression vector and successfully expressed in the transfected cultured cells. Expression of V-val EBNA1 rendered 293 cells able to undergo serum‑independent cell proliferation, providing them with anti-apoptotic abilities, which are two characteristics of cancer cells. These data suggested that use of EBNA1 originally derived from tumor cells, rather than the more commonly utilized prototype, when investigating the potential role of EBNA1 in the oncogenesis of EBV-associated malignancies, is crucial.

View Figures

View References

1	Young LS and Murray PG: Epstein-Barr virus and oncogenesis: from latent genes to tumours. Oncogene. 22:5108–5121. 2003. View Article : Google Scholar : PubMed/NCBI
2	Schepers A, Ritzi M, Bousset K, et al: Human origin recognition complex binds to the region of the latent origin of DNA replication of Epstein-Barr virus. EMBO J. 20:4588–4602. 2001. View Article : Google Scholar : PubMed/NCBI
3	Sears J, Kolman J, Wahl GM and Aiyar A: Metaphase chromosome tethering is necessary for the DNA synthesis and maintenance of oriP plasmids but is insufficient for transcription activation by Epstein-Barr nuclear antigen 1. J Virol. 77:11767–11780. 2003. View Article : Google Scholar : PubMed/NCBI
4	Nanbo A, Sugden A and Sugden B: The coupling of synthesis and partitioning of EBV’s plasmid replicon is revealed in live cells. EMBO J. 26:4252–4262. 2007. View Article : Google Scholar : PubMed/NCBI
5	Sugden B and Warren N: A promoter of Epstein-Barr virus that can function during latent infection can be transactivated by EBNA-1, a viral protein required for viral DNA replication during latent infection. J Virol. 63:2644–2649. 1989.PubMed/NCBI
6	Altmann M, Pich D, Ruiss R, Wang J, Sugden B and Hammerschmidt W: Transcriptional activation by EBV nuclear antigen 1 is essential for the expression of EBV’s transforming genes. Proc Natl Acad Sci USA. 103:14188–14193. 2006. View Article : Google Scholar
7	Gahn TA and Sugden B: An EBNA-1-dependent enhancer acts from a distance of 10 kilobase pairs to increase expression of the Epstein-Barr virus LMP gene. J Virol. 69:2633–2636. 1995.PubMed/NCBI
8	Sample J, Henson EB and Sample C: The Epstein-Barr virus nuclear protein 1 promoter active in type I latency is autoregulated. J Virol. 66:4654–4661. 1992.PubMed/NCBI
9	Sung NS, Wilson J, Davenport M, Sista ND and Pagano JS: Reciprocal regulation of the Epstein-Barr virus BamHI-F promoter by EBNA-1 and an E2F transcription factor. Mol Cell Biol. 14:7144–7152. 1994.PubMed/NCBI
10	Frappier L: Role of EBNA1 in NPC tumourigenesis. Semin Cancer Biol. 22:154–161. 2012. View Article : Google Scholar
11	Westhoff Smith D and Sugden B: Potential cellular functions of Epstein-Barr nuclear antigen 1 (EBNA1) of Epstein-Barr virus. Viruses. 5:226–240. 2013. View Article : Google Scholar : PubMed/NCBI
12	Kennedy G, Komano J and Sugden B: Epstein-Barr virus provides a survival factor to Burkitt’s lymphomas. Proc Natl Acad Sci USA. 100:14269–14274. 2003. View Article : Google Scholar
13	Holowaty MN, Zeghouf M, Wu H, et al: Protein profiling with Epstein-Barr nuclear antigen-1 reveals an interaction with the herpesvirus-associated ubiquitin-specific protease HAUSP/USP7. J Biol Chem. 278:29987–29994. 2003. View Article : Google Scholar : PubMed/NCBI
14	Holowaty MN, Sheng Y, Nguyen T, Arrowsmith C and Frappier L: Protein interaction domains of the ubiquitin-specific protease, USP7/HAUSP. J Biol Chem. 278:47753–47761. 2003. View Article : Google Scholar : PubMed/NCBI
15	Wilson JB, Bell JL and Levine AJ: Expression of Epstein-Barr virus nuclear antigen-1 induces B cell neoplasia in transgenic mice. EMBO J. 15:3117–3126. 1996.PubMed/NCBI
16	Murakami M, Lan K, Subramanian C and Robertson ES: Epstein-Barr virus nuclear antigen 1 interacts with Nm23-H1 in lymphoblastoid cell lines and inhibits its ability to suppress cell migration. J Virol. 79:1559–1568. 2005. View Article : Google Scholar : PubMed/NCBI
17	Kaul R, Murakami M, Choudhuri T and Robertson ES: Epstein-Barr virus latent nuclear antigens can induce metastasis in a nude mouse model. J Virol. 81:10352–10361. 2007. View Article : Google Scholar : PubMed/NCBI
18	O’Neil JD, Owen TJ, Wood VH, et al: Epstein-Barr virus-encoded EBNA1 modulates the AP-1 transcription factor pathway in nasopharyngeal carcinoma cells and enhances angiogenesis in vitro. J Gen Virol. 89:2833–2842. 2008. View Article : Google Scholar
19	Wood VH, O’Neil JD, Wei W, Stewart SE, Dawson CW and Young LS: Epstein-Barr virus-encoded EBNA1 regulates cellular gene transcription and modulates the STAT1 and TGFbeta signaling pathways. Oncogene. 26:4135–4147. 2007. View Article : Google Scholar : PubMed/NCBI
20	Flavell JR, Baumforth KR, Wood VH, et al: Down-regulation of the TGF-beta target gene, PTPRK, by the Epstein-Barr virus encoded EBNA1 contributes to the growth and survival of Hodgkin lymphoma cells. Blood. 111:292–301. 2008. View Article : Google Scholar
21	Valentine R, Dawson CW, Hu C, et al: Epstein-Barr virus-encoded EBNA1 inhibits the canonical NF-kappaB pathway in carcinoma cells by inhibiting IKK phosphorylation. Mol Cancer. 9:12010. View Article : Google Scholar : PubMed/NCBI
22	Gruhne B, Sompallae R, Marescotti D, Kamranvar SA, Gastaldello S and Masucci MG: The Epstein-Barr virus nuclear antigen-1 promotes genomic instability via induction of reactive oxygen species. Proc Natl Acad Sci USA. 106:2313–2318. 2009. View Article : Google Scholar : PubMed/NCBI
23	Gruhne B, Sompallae R and Masucci MG: Three Epstein-Barr virus latency proteins independently promote genomic instability by inducing DNA damage, inhibiting DNA repair and inactivating cell cycle checkpoints. Oncogene. 28:3997–4008. 2009. View Article : Google Scholar : PubMed/NCBI
24	Hennessy K and Kieff E: One of two Epstein-Barr virus nuclear antigens contains a glycine-alanine copolymer domain. Proc Natl Acad Sci USA. 80:5665–5669. 1983. View Article : Google Scholar : PubMed/NCBI
25	Hennessy K, Heller M, van Santen V and Kieff E: Simple repeat array in Epstein-Barr virus DNA encodes part of the Epstein-Barr nuclear antigen. Science. 220:1396–1398. 1983. View Article : Google Scholar : PubMed/NCBI
26	Allday MJ and MacGillivray AJ: Epstein-Barr virus nuclear antigen (EBNA): size polymorphism of EBNA 1. J Gen Virol. 66:1595–1600. 1985. View Article : Google Scholar : PubMed/NCBI
27	Levitskaya J, Coram M, Levitsky V, et al: Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature. 375:685–688. 1995. View Article : Google Scholar : PubMed/NCBI
28	Snudden DK, Smith PR, Lai D, Ng MH and Griffin BE: Alterations in the structure of the EBV nuclear antigen, EBNA1, in epithelial cell tumours. Oncogene. 10:1545–1552. 1995.PubMed/NCBI
29	Chang CM, Yu KJ, Mbulaiteye SM, Hildesheim A and Bhatia K: The extent of genetic diversity of Epstein-Barr virus and its geographic and disease patterns: a need for reappraisal. Virus Res. 143:209–221. 2009. View Article : Google Scholar : PubMed/NCBI
30	Gutiérrez MI, Raj A, Spangler G, et al: Sequence variations in EBNA-1 may dictate restriction of tissue distribution of Epstein-Barr virus in normal and tumour cells. J Gen Virol. 78:1663–1670. 1997.PubMed/NCBI
31	Sandvej K, Zhou XG and Hamilton-Dutoit S: EBNA-1 sequence variation in Danish and Chinese EBV-associated tumours: evidence for geographical polymorphism but not for tumour-specific subtype restriction. J Pathol. 191:127–131. 2000. View Article : Google Scholar : PubMed/NCBI
32	Wang JT, Sheeng TS, Su IJ, Chen JY and Chen MR: EBNA-1 sequence variations reflect active EBV replication and disease status or quiescent latency in lymphocytes. J Med Virol. 69:417–425. 2003. View Article : Google Scholar : PubMed/NCBI
33	Do NV, Ingemar E, Phi PT, et al: A major EBNA1 variant from Asian EBV isolates shows enhanced transcriptional activity compared to prototype B95.8. Virus Res. 132:15–24. 2008. View Article : Google Scholar
34	Habeshaw G, Yao QY, Bell AI, Morton D and Rickinson AB: Epstein-Barr virus nuclear antigen 1 sequences in endemic and sporadic Burkitt’s lymphoma reflect virus strains prevalent in different geographic areas. J Virol. 73:965–975. 1999.PubMed/NCBI
35	Mai SJ, Xie D, Huang YF, et al: The enhanced transcriptional activity of the V-val subtype of Epstein-Barr virus nuclear antigen 1 in epithelial cell lines. Oncol Rep. 23:1417–1424. 2010.PubMed/NCBI
36	Zhang XS, Wang HH, Hu LF, et al: V-val subtype of Epstein-Barr virus nuclear antigen 1 preferentially exists in biopsies of nasopharyngeal carcinoma. Cancer Lett. 211:11–18. 2004. View Article : Google Scholar : PubMed/NCBI
37	Wang WY, Chien YC, Jan JS, Chueh CM and Lin JC: Consistent sequence variation of Epstein-Barr virus nuclear antigen 1 in primary tumor and peripheral blood cells of patients with nasopharyngeal carcinoma. Clin Cancer Res. 8:2586–2590. 2002.PubMed/NCBI
38	Chang YS, Shih LY, Peng CL, Chen SH and Liu ST: Characterization of two newly established EBV-containing lymphoblastoid cell lines from patients with myeloid leukemias. Leuk Res. 14:309–320. 1990. View Article : Google Scholar : PubMed/NCBI
39	Miller G, Shope T, Lisco H, Stitt D and Lipman M: Epstein-Barr virus: transformation, cytopathic changes, and viral antigens in squirrel monkey and marmoset leukocytes. Proc Natl Acad Sci USA. 69:383–387. 1972. View Article : Google Scholar : PubMed/NCBI
40	Pulvertaft JV: A study of malignant tumours in Nigeria by shortterm tissue culture. J Clin Pathol. 18:261–273. 1965. View Article : Google Scholar : PubMed/NCBI
41	Hinuma Y and Grace JT Jr: Cloning of immunoglobulin-producing human leukemic and lymphoma cells in long-term cultures. Proc Soc Exp Biol Med. 124:107–111. 1967. View Article : Google Scholar : PubMed/NCBI
42	Arrand JR, Walsh-Arrand JE and Rymo L: Cytoplasmic RNA from normal and malignant human cells shows homology to the DNAs of Epstein-Barr virus and human adenoviruses. EMBO J. 2:1673–1683. 1983.PubMed/NCBI
43	Graham FL, Smiley J, Russell WC and Nairn R: Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol. 36:59–74. 1977. View Article : Google Scholar : PubMed/NCBI
44	Baer R, Bankier AT, Biggin MD, et al: DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature. 310:207–211. 1984. View Article : Google Scholar : PubMed/NCBI
45	Wang TC and Chao M: Molecular cloning and expression of the hepatitis delta virus genotype IIb genome. Biochem Biophys Res Commun. 303:357–363. 2003. View Article : Google Scholar : PubMed/NCBI
46	Bhatia K, Raj A, Guitierrez MI, et al: Variation in the sequence of Epstein-Barr virus nuclear antigen 1 in normal peripheral blood lymphocytes and in Burkitt’s lymphomas. Oncogene. 13:177–181. 1996.PubMed/NCBI
47	Chen MR, Tsai CH, Wu FF, Kan SH, Yang CS and Chen JY: The major immunogenic epitopes of Epstein-Barr virus (EBV) nuclear antigen 1 are encoded by sequence domains which vary among nasopharyngeal carcinoma biopsies and EBV-associated cell lines. J Gen Virol. 80:447–455. 1999.PubMed/NCBI
48	Niedobitek G: Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma. Mol Pathol. 53:248–254. 2000. View Article : Google Scholar : PubMed/NCBI
49	Mai SJ, Ooka T, Li DJ, et al: Functional advantage of NPC-related V-val subtype of Epstein-Barr virus nuclear antigen 1 compared with prototype in epithelial cell line. Oncol Rep. 17:141–146. 2007.
50	de Thé G: Nasopharyngeal carcinoma. Viral Infections of Humans, Epidemiology and Control. Evans AS and Kazslow RA: 4th edition. Plenum Medical Book Co; New York, NY: pp. 935–967. 1997, View Article : Google Scholar